Literature DB >> 27350005

[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer].

Wolfgang P Fendler, Clemens Kratochwil, Hojjat Ahmadzadehfar, Kambiz Rahbar, Richard P Baum, Matthias Schmidt, Andreas Pfestroff, Ulf Lützen, Vikas Prasad, Alexander Heinzel, Martin Heuschkel, Juri Ruf, Peter Bartenstein, Bernd J Krause1.   

Abstract

Radioligand therapy (RLT) using 177Lu labelled inhibitors of the prostate-specific membrane antigen (177Lu-PSMA) is performed in patients with metastatic castration-resistant prostate cancer (mCRPC) after exhaustion of other options. German University Clinics offer RLT since 2013 on a compassionate use basis. The present consensus document includes recommendations for RLT with 177Lu-PSMA-617. These consensus statements were developed by an expert panel formed by the German Society of Nuclear Medicine (DGN) in December 2015. Statements include recommendations for indication, baseline tests, therapy protocol, concomitant therapy, dosimetry, and follow-up. Consensus recommendations aim to inform the attending medical staff, standardize 177Lu-PSMA-617 RLT, and improve quality of individual patient care.

Entities:  

Keywords:  Consensus; PSMA; lutetium; prostate cancer; radioligand therapy

Mesh：

Substances：

Year:  2016        PMID： 27350005

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN： 0029-5566            Impact factor:   1.379


  34 in total

1.  177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer.

Authors:  Axel Bräuer; Lena Sophie Grubert; Wolfgang Roll; Andres Jan Schrader; Michael Schäfers; Martin Bögemann; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-17       Impact factor: 9.236

Review 2.  [177Lu-PSMA therapy : Current evidence for use in the treatment of patients with metastatic prostate cancer].

Authors:  M Boegemann; A J Schrader; K Rahbar
Journal:  Urologe A       Date:  2017-11       Impact factor: 0.639

3.  Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer.

Authors:  Kambiz Rahbar; Martin Bögeman; Anna Yordanova; Maria Eveslage; Michael Schäfers; Markus Essler; Hojjat Ahmadzadehfar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-13       Impact factor: 9.236

4.  [Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein].

Authors:  H Ahmadzadehfar; P Albers; A Bockisch; M Boegemann; C Böhme; W Burchert; M Dietlein; A Drzezga; U Fabry; G Feldmann; A Heidenreich; A Heinzel; K Herrmann; A Heyll; C Höhling; C Kreuzer; D Laufer; R Mengel; F M Mottaghy; H-W Müller; S C Müller; E Ost; K Rahbar; W Reifenhäuser; M Schäfers; C Schlenkhoff; M Schmidt; I Schmidt-Wolf; C Wildenhain; B Zimmer; M Essler
Journal:  Urologe A       Date:  2018-06       Impact factor: 0.639

5.  Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer.

Authors:  Anna Yordanova; Paula Linden; Stefan Hauser; Michael Meisenheimer; Stefan Kürpig; Georg Feldmann; Florian C Gaertner; Markus Essler; Hojjat Ahmadzadehfar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-11-24       Impact factor: 9.236

6.  68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.

Authors:  Alexander Heinzel; Dima Boghos; Felix M Mottaghy; Florian Gaertner; Markus Essler; Dirk von Mallek; Hojjat Ahmadzadehfar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-29       Impact factor: 9.236

7.  Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer.

Authors:  Wolfgang P Fendler; Andreea D Stuparu; Susan Evans-Axelsson; Katharina Lückerath; Liu Wei; Woosuk Kim; Soumya Poddar; Jonathan Said; Caius G Radu; Matthias Eiber; Johannes Czernin; Roger Slavik; Ken Herrmann
Journal:  J Nucl Med       Date:  2017-05-25       Impact factor: 10.057

Review 8.  Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.

Authors:  Harshad R Kulkarni; Aviral Singh; Thomas Langbein; Christiane Schuchardt; Dirk Mueller; Jingjing Zhang; Coline Lehmann; Richard P Baum
Journal:  Br J Radiol       Date:  2018-06-01       Impact factor: 3.039

9.  Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer.

Authors:  Katharina Lückerath; Andreea D Stuparu; Liu Wei; Woosuk Kim; Caius G Radu; Christine E Mona; Jeremie Calais; Matthew Rettig; Robert E Reiter; Johannes Czernin; Roger Slavik; Ken Herrmann; Matthias Eiber; Wolfgang P Fendler
Journal:  J Nucl Med       Date:  2018-03-30       Impact factor: 10.057

Review 10.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.